‘Much-needed hope’ as CRISPR gene editing therapy recommended for sickle cell disease
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS. View on euronews
NHS England to offer Casgevy for sickle cell disease patients
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by approval for transfusion-dependent beta-thalassemia (TDT) in January 2024. NHS England reached an earlier reimbursement agreement for Casgevy in TDT in August 2024.
Sickle cell disease ‘cure’ to be offered to NHS patients
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to treat sickle cell disease. Read more here.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the U.K. and Vertex.
After inversion by CRISPR/Cas, the epigenetic state of plant chromosomes remains stable
The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...
MIT Technology Review2d
Mice with two dads have been created using CRISPR
It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.
News Medical on MSN20m
Researchers create random versions of human genomes to study disease
The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.
STAT8d
RFK Jr., an investor in a CRISPR biotech, has raised alarms about the technology
RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.
MIT Technology Review2d
The Download: mice with two dads, and Meta’s fact-checking challenges
Once a week, Sun Kai has a video call with his mother, and they discuss his day-to-day life. But Sun’s mother died five years ...
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...
GEN7h
Next-Gen Cas12a System Enables Precise Single and Multiplexed Gene Editing in Cancer
Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.
Yahoo Finance2d
CRISPR Therapeutics AG (CRSP)
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...
Crispr Therapeutics price target lowered to $30 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...
Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why
We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...